Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GoHealth Reports Fourth Quarter and Fiscal 2021 Results

      GoHealth, Inc. (PRNewsfoto/GoHealth, Inc.)

      News provided by

      GoHealth, Inc.

      Mar 15, 2022, 16:05 ET

      Share this article

      Share this article


      Focusing on Optimization in 2022

      CHICAGO, March 15, 2022 /PRNewswire/ -- GoHealth, Inc. (Nasdaq: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and twelve months ended December 31, 2021.

      • Fourth quarter 2021 net revenue of $449.6 million increased 1% compared to the prior year period, and fiscal year 2021 net revenue of $1,062.4 million increased 21% compared to the prior year period. These are inclusive of an incremental 15% Medicare Advantage ('MA") lifetime value ("LTV") constraint applied to all MA policies sold in the fourth quarter of 2021 and negative revenue adjustments relating to performance obligations satisfied in 2018, 2019, 2020, and the first nine months of 2021 (the "Lookback Adjustments") of $155.0 million for the fourth quarter of 2021 and $165.3 million for the year ended December 31, 2021, as further described below.
      • Fourth quarter 2021 net loss of $432.3 million and fiscal year 2021 net loss of $534.2 million, inclusive of $386.6 million of goodwill impairment charges.  
      • Fourth quarter 2021 Adjusted EBITDA1 of $1.5 million decreased 99% compared to the prior year period, and fiscal year 2021 Adjusted EBITDA1 of $33.8 million decreased 88% compared to the prior year period. Adjusted EBITDA1 includes the negative impact of the Lookback Adjustments for both the fourth quarter of 2021 and the year ended December 31, 2021 and is inclusive of an incremental 15% constraint applied to all MA policies sold in the fourth quarter of 2021. 
      • Fourth quarter 2021 MA Carrier Approved Submissions ("CAS") of 653,620 increased 99% compared to the prior year period, and fiscal year 2021 MA CAS's of 1,170,603 increased 84% compared to the prior year period.
      • Negative revenue Lookback Adjustments were $155.0 million for the fourth quarter of 2021 and $165.3 million for the year ended December 31, 2021.
      • The Company provided its full year 2022 outlook, and expects total net revenue of $900 - $1,100 million (-15% to +4%) powered by commission revenue of $700 - $900 million (-21% to +2%). The company expects Adjusted EBITDA1 of $110 - $150 million (+224% to +343%).  The Company also expects negative cash flow from operations of $50 - $10 million (+83% to +97%). 

      2021 Highlights3

      • Total company revenue grew 21% to $1,062.4 million
        • Total Medicare Submitted Policies2 grew 75% during 2021 to 1,273,859
      • Medicare—Internal revenue increased 27% to $844.9 million
        • Medicare—Internal segment profit decreased 72% to $84.3 million, with a 10% margin
      • Encompass revenue of $72 million
      • Adjusted EBITDA1 decreased 88% to $33.8 million, resulting in full-year Adjusted EBITDA margins of 3%
      • LTV per carrier Approved MA Submission decreased 7% from $900 in 2020 to $842 in 2021, adjusted for the impact of the Lookback Adjustments
      • Grew commissions receivable balance by $452.1 million (+56%) in 2021 to $1,262.5 million

      Fourth Quarter AEP Highlights3

      • Total company revenue grew 1% to $449.6 million
        • Total Medicare Submitted Policies grew 93% during the fourth quarter to 723,884
      • Medicare—Internal revenue increased 5% to $368.5 million
        • Medicare—Internal segment profit decreased 94% to $10.8 million, with a 3% margin
      • Adjusted EBITDA1 decreased 99% to $1.5 million, resulting in Adjusted EBITDA margins of 0.3%
        • LTV per carrier Approved MA Submission decreased 15% from $949 in the fourth quarter of 2020 to $810 in the fourth quarter of 2021, adjusted for the impact of the Lookback Adjustments

      2022 Financial Outlook

      The trajectory of the US economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. The Company has provided its financial outlook for the fiscal year ending December 31, 2022 based on current market conditions and expectations:

      • Full-year 2022 net revenue of $900 - $1,100 million, representing year-over-year growth of (15)% - 4%
        • Full-year 2022 commission revenue of $700 - $900 million, representing year-over-year growth of (21)% - 2%, fueled by the Company's continued investment in its Medicare business
      • Full-year 2022 Adjusted EBITDA of $110 - $150 million, representing year-over-year growth of 224% - 343%
      • Full-year 2022 cash flow from operations of ($50) - ($10) million, representing year-over-year improvement of 83% to 97%

      Conference Call Details
      The Company will host a conference call today, Tuesday, March 15, 2022 at 5:00 p.m. (ET) to discuss its financial results. A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 2679849. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

      About GoHealth, Inc.:
      As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. GoHealth has enrolled millions of people in Medicare and individual and family plans. For more information, visit https://www.gohealth.com.

      Investor Relations:
      [email protected]

      Media Relations:
      [email protected]


      (1)

      Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

      (2)

      Total Medicare Advantage Submitted Policies includes Commissionable and non-Commissionable Policies.

      (3)

      Fourth quarter and fiscal year 2021 results compared to the comparable prior year period.

      Forward-Looking Statements

      This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations often include forwarding-looking statements, including, but not limited to, statements regarding expected financial performance and operational performance, including with respect to revenue and Adjusted EBITDA, the growth of our membership base, our ability to realize the potential of our market opportunity, and 2022 annual guidance. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationship, reduction in revenue or consolidation of carriers; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; our ability to obtain the capital needed to operate and grow our business; attracting qualified employees and retaining key employees; and the impact of global economic conditions. The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict and are reliant on the actions taken or to be taken by third parties. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, including any guidance provided. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      In  addition, the Company is required to comply with  Accounting Standards Codification 606 – Revenue from Contracts with Customers.  This standard requires the Company to make numerous assumptions  that are based upon historical trends and management's judgment.  These assumptions may change over time and may have a material impact on revenue recognition, guidance and results of operations.  Please review our assumptions stated in this press release careful as well as our associated risk factors in our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.    You can obtain copies of GoHealth's filings with the SEC for free at the SEC's website (www.SEC.gov). 

      Use of Non-GAAP Financial Measures and Key Performance Indicators

      In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense, or EBITDA; Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

      Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for goodwill impairment charges, share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, one time indirect costs in connection with our IPO, and severance costs. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

      We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

      The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

      Management has provided its outlook and guidance regarding adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Management has not reconciled these non-GAAP financial measures to the corresponding GAAP financial measures because guidance for the various reconciling items are not provided. Management is unable to provide guidance for these reconciling items because we cannot determine their probable significance, as certain items are outside of our control and cannot be reasonably predicted since these items could vary significantly from period to period. Accordingly, reconciliations to the corresponding GAAP financial measures are not available without unreasonable effort.

      Glossary

      "Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for goodwill impairment charges, share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, one time indirect costs in connection with our IPO, and severance costs.

      "Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

      "Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

      "LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

      "Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

      The following tables set forth the components of our results of operations for the periods indicated (unaudited):

      (in thousands, except percentages and per share amounts)


      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $  384,826


      85.6%


      $  360,634


      80.9%


      $      24,192


      6.7%

      Enterprise


      64,774


      14.4%


      85,289


      19.1%


      (20,515)


      (24.1)%

      Net revenues


      449,600


      100.0%


      445,923


      100.0%


      3,677


      0.8%

      Operating expenses:













      Cost of revenue


      99,886


      22.2%


      94,682


      21.2%


      5,204


      5.5%

      Marketing and advertising


      195,411


      43.5%


      96,309


      21.6%


      99,102


      102.9%

      Customer care and enrollment


      123,331


      27.4%


      60,229


      13.5%


      63,102


      104.8%

      Technology


      15,178


      3.4%


      9,530


      2.1%


      5,648


      59.3%

      General and administrative


      29,007


      6.5%


      19,828


      4.4%


      9,179


      46.3%

      Amortization of intangible assets


      23,513


      5.2%


      23,514


      5.3%


      (1)


      —%

      Goodwill impairment charges


      386,553


      86.0%


      —


      —%


      386,553


      NM

      Total operating expenses


      872,879


      194.1%


      304,092


      68.2%


      568,787


      187.0%

      Income (loss) from operations


      (423,279)


      (94.1)%


      141,831


      31.8%


      (565,110)


      (398.4)%

      Interest expense


      9,619


      2.1%


      8,591


      1.9%


      1,028


      12.0%

      Other expense (income), net


      (696)


      (0.2)%


      135


      —%


      (831)


      NM

      Income (loss) before income taxes


      (432,202)


      (96.1)%


      133,105


      29.8%


      (565,307)


      (424.7)%

      Income tax expense (benefit)


      118


      —%


      5


      —%


      113


      NM

      Net income (loss)


      $ (432,320)


      (96.2)%


      $  133,100


      29.8%


      $    (565,420)


      (424.8)%

      Net income (loss) attributable to noncontrolling interests


      (277,225)


      (61.7)%


      97,143


      21.8%


      (374,368)


      (385.4)%

      Net income (loss) attributable to GoHealth, Inc.


      $ (155,095)


      (34.5)%


      $    35,957


      8.1%


      $    (191,052)


      (531.3)%

      Net income (loss) per share:













      Net income (loss) per share of common stock — basic


      $      (1.35)




      $       0.43







      Net income (loss) per share of common stock — diluted (1)


      $      (1.35)




      $       0.41







      Weighted-average shares of common stock outstanding — basic


      115,045




      84,194







      Weighted-average shares of common stock outstanding — diluted


      115,045




      321,191







      Non-GAAP financial measures:













      EBITDA


      $ (392,251)




      $  166,806







      Adjusted EBITDA


      $     1,499




      $  169,889







      Adjusted EBITDA margin


      0.3%




      38.1%















      NM = Not meaningful

      (1)

      Net income per share of common stock - diluted for the three months ending December 31, 2020, of $0.41 is calculated by dividing net income of $133.1 million, which considers the reallocation of earnings after the assumed conversion of Class B Common Stock for Class A Common Stock, by the weighted-average shares of common stock outstanding - diluted of 321,191.

      (in thousands, except percentages and per share amounts)


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $  881,263


      82.9%


      $  671,140


      76.5%


      $     210,123


      31.3%

      Enterprise


      181,152


      17.1%


      206,210


      23.5%


      (25,058)


      (12.2)%

      Net revenues


      1,062,415


      100.0%


      877,350


      100.0%


      185,065


      21.1%

      Operating expenses:













      Cost of revenue


      239,335


      22.5%


      199,202


      22.7%


      40,133


      20.1%

      Marketing and advertising


      365,141


      34.4%


      206,864


      23.6%


      158,277


      76.5%

      Customer care and enrollment


      320,165


      30.1%


      165,497


      18.9%


      154,668


      93.5%

      Technology


      48,429


      4.6%


      59,348


      6.8%


      (10,919)


      (18.4)%

      General and administrative


      98,183


      9.2%


      197,229


      22.5%


      (99,046)


      (50.2)%

      Change in fair value of contingent consideration liability


      —


      —%


      19,700


      2.2%


      (19,700)


      (100.0)%

      Amortization of intangible assets


      94,056


      8.9%


      94,056


      10.7%


      —


      —%

      Goodwill impairment charges


      386,553


      36.4%


      —


      —%


      386,553


      NM

      Total operating expenses


      1,551,862


      146.1%


      941,896


      107.4%


      609,966


      64.8%

      Income (loss) from operations


      (489,447)


      (46.1)%


      (64,546)


      (7.4)%


      (424,901)


      658.3%

      Interest expense


      33,505


      3.2%


      32,969


      3.8%


      536


      1.6%

      Loss on extinguishment of debt


      11,935


      1.1%


      —


      —%


      11,935


      NM

      Other (income) expense


      (669)


      (0.1)%


      (358)


      —%


      (311)


      86.9%

      Income (loss) before income taxes


      (534,218)


      (50.3)%


      (97,157)


      (11.1)%


      (437,061)


      449.9%

      Income tax expense (benefit)


      (24)


      —%


      43


      —%


      (67)


      (155.8)%

      Net income (loss)


      $ (534,194)


      (50.3)%


      $   (97,200)


      (11.1)%


      $    (436,994)


      449.6%

      Net loss attributable to noncontrolling interests


      (344,837)


      (32.5)%


      (52,933)


      (6.0)%





      Net loss attributable to GoHealth, Inc.


      $ (189,357)


      (17.8)%


      $   (44,267)


      (5.0)%





      Net income (loss) per share:













      Net income (loss) per share of common stock — basic and diluted


      $      (1.79)




      $      (0.22)







      Weighted-average shares of common stock outstanding — basic and diluted


      105,991




      84,189







      Non-GAAP financial measures:













      EBITDA


      $ (393,206)




      $    34,364







      Adjusted EBITDA


      $    33,821




      $  271,029







      Adjusted EBITDA margin


      3.2%




      30.9%








      NM = Not meaningful


      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

      (in thousands, except percentages)


      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020

      Net revenues


      $    449,600


      $    445,923

      Net income (loss)


      (432,320)


      133,100

      Interest expense


      9,619


      8,591

      Income tax expense


      118


      5

      Depreciation and amortization expense


      30,332


      25,110

      EBITDA


      (392,251)


      166,806

      Goodwill impairment charges (1)


      386,553


      —

      Share-based compensation expense (2)


      7,197


      3,083

      Adjusted EBITDA


      $        1,499


      $    169,889

      Adjusted EBITDA margin


      0.3%


      38.1%









      (1)

      Represents goodwill impairment charges related to the Medicare— Internal and Medicare— External reporting units for the three months ended December 31, 2021.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (in thousands, except percentages)


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Net revenues


      $  1,062,415


      $    877,350

      Net income (loss)


      (534,194)


      (97,200)

      Interest expense


      33,505


      32,969

      Income tax expense (benefit)


      (24)


      43

      Depreciation and amortization expense


      107,507


      98,552

      EBITDA


      (393,206)


      34,364

      Loss on extinguishment of debt (1)


      11,935


      —

      Goodwill impairment charges (2)


      386,553


      —

      Share-based compensation expense (3)


      27,297


      6,929

      Loss on sublease (4)


      1,062


      —

      Legal fees (5)


      180


      —

      Accelerated vesting of certain equity awards (6)


      —


      209,300

      Change in fair value of contingent consideration liability (7)


      —


      19,700

      IPO transactions costs (8)


      —


      659

      Severance costs (9)


      —


      77

      Adjusted EBITDA


      $      33,821


      $    271,029

      Adjusted EBITDA margin


      3.2%


      30.9%









      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents goodwill impairment charges related to the Medicare— Internal and Medicare— External reporting units for the twelve months ended December 31, 2021.

      (3)

      Represents non-cash share-based compensation expense relating to equity awards.

      (4)

      Represents the loss related to a sublease agreement entered into during the twelve months ended December 31, 2021.

      (5)

      Represents non-recurring legal fees unrelated to our core operations.

      (6)

      Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the twelve months ended December 31, 2020.

      (7)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (8)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (9)

      Represents costs associated with the termination of employment.


      The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

      (in thousands)


      Successor


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Marketing and advertising


      $          2,108


      $         24,890

      Customer care and enrollment


      3,775


      12,599

      Technology


      3,775


      33,085

      General and administrative


      17,639


      145,655

      Total share-based compensation expense


      $         27,297


      $       216,229

      The following table sets forth our balance sheets for the periods indicated (unaudited):

      (in thousands, except per share amounts)


      Dec. 31, 2021


      Dec. 31, 2020

      Assets





      Current assets:





      Cash and cash equivalents


      $         84,361


      $       144,234

      Accounts receivable, net of allowance for doubtful accounts of $558 in 2021 and $787 in 2020


      17,276


      14,211

      Receivable from NVX Holdings, Inc.


      —


      3,395

      Commissions receivable - current


      268,663


      188,128

      Prepaid expense and other current assets


      58,695


      41,854

      Total current assets


      428,995


      391,822

      Commissions receivable - non-current


      993,844


      622,270

      Operating Lease ROU Asset


      23,462


      —

      Other long-term assets


      3,608


      2,072

      Property, equipment, and capitalized software, net


      24,273


      17,353

      Intangible assets, net


      594,669


      688,726

      Goodwill


      —


      386,553

      Total assets


      $    2,068,851


      $    2,108,796

      Liabilities and Stockholders' Equity





      Current liabilities:





      Accounts payable


      $         39,843


      $          8,733

      Accrued liabilities


      52,788


      26,926

      Commissions payable - current


      104,160


      78,478

      Short-term operating lease liability


      6,126


      —

      Deferred revenue


      536


      736

      Current portion of long-term debt


      5,270


      4,170

      Other current liabilities


      8,344


      8,328

      Total current liabilities


      217,067


      127,371

      Non-current liabilities:





      Commissions payable - non-current


      274,403


      182,596

      Long-term operating lease liability


      19,776


      —

      Long-term debt, net of current portion


      665,115


      396,400

      Other non-current liabilities


      —


      3,274

      Total non-current liabilities


      959,294


      582,270

      Stockholders' equity:





      Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 115,487  and 84,196 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.


      11


      8

      Class B common stock – $0.0001 par value; 587,360 and 619,004 shares authorized; 205,352 and 236,997 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.


      21


      24

      Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at December 31, 2021 and December 31, 2020


      —


      —

      Additional paid-in capital


      561,447


      399,169

      Accumulated other comprehensive income (loss)


      (59)


      17

      Accumulated deficit


      (208,317)


      (18,802)

      Total stockholders' equity attributable to GoHealth, Inc.


      353,103


      380,416

      Non-controlling interests


      539,387


      1,018,739

      Total stockholders' equity


      892,490


      1,399,155

      Total liabilities and stockholders' equity


      $    2,068,851


      $    2,108,796

      The following table sets forth our statements of cash flows for the periods indicated (unaudited):

      (in thousands)


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Operating Activities





      Net income (loss)


      $      (534,194)


      $        (97,200)

      Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:





      Share-based compensation


      27,297


      216,229

      Depreciation and amortization


      13,451


      4,496

      Amortization of intangible assets


      94,056


      94,056

      Amortization of debt discount and issuance costs


      2,222


      2,430

      Loss on extinguishment of debt


      11,935


      —

      Loss on sublease


      1,062


      —

      Change in fair value of contingent consideration


      —


      19,700

      Goodwill impairment charges


      386,553


      —

      Non-cash lease expense


      5,033


      —

      Other non-cash items


      (5)


      (1,691)

      Changes in assets and liabilities, net of acquisition:





      Accounts receivable


      (2,758)


      4,526

      Commissions receivable


      (452,950)


      (427,467)

      Prepaid expenses and other assets


      (18,613)


      (30,194)

      Accounts payable


      30,477


      (5,340)

      Accrued liabilities


      25,745


      4,358

      Deferred revenue


      (200)


      (14,482)

      Commissions payable


      117,489


      107,583

      Operating lease liabilities


      (4,885)


      —

      Other liabilities


      (721)


      8,779

      Net cash provided by (used in) operating activities


      (299,006)


      (114,217)

      Investing Activities





      Acquisition of business, net of cash


      —


      —

      Purchases of property, equipment and software


      (19,801)


      (14,523)

      Net cash provided by (used in) investing activities


      (19,801)


      (14,523)

      Financing Activities





      Proceeds from issuance of Class A common stock sold in initial public offering, net of offering costs


      —


      852,407

      Payment of partial consideration to Blocker Shareholders in the Blocker Merger


      —


      (96,165)

      Purchase of LLC Interests from Continuing Equity Owners


      —


      (508,320)

      Settlement of Senior Preferred Earnout Units


      —


      (100,000)

      Proceeds received upon issuance of preferred units


      —


      —

      Proceeds received upon issuance of common units


      —


      10,000

      Proceeds from borrowings


      565,000


      117,000

      Repayment of borrowings


      (298,970)


      (3,878)

      Call premium paid for debt extinguishment


      (5,910)


      —

      Debt issuance cost payments


      (4,108)


      (6,293)

      Principal payments under capital lease obligations


      (318)


      (293)

      Distributions to non-controlling interests


      —


      (400)

      Advancement to NVX Holdings, Inc.


      3,395


      (3,395)

      Net cash provided by (used in) financing activities


      259,089


      260,663

      Effect of exchange rate changes on cash and cash equivalents


      (155)


      35

      Increase (decrease) in cash and cash equivalents


      (59,873)


      131,958

      Cash and cash equivalents at beginning of period


      144,234


      12,276

      Cash and cash equivalents at end of period


      $         84,361


      $       144,234

      The following tables set forth operating segment results for the periods indicated (unaudited):

      (in thousands, except percentages)


      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Medicare - Internal


      $       368,503


      82.0%


      $       351,082


      78.7%


      $        17,421


      5.0%

      Medicare - External


      72,447


      16.1%


      78,355


      17.6%


      (5,908)


      (7.5)%

      IFP and Other - Internal


      6,182


      1.4%


      10,473


      2.3%


      (4,291)


      (41.0)%

      IFP and Other - External


      2,468


      0.5%


      6,013


      1.3%


      (3,545)


      (59.0)%

      Net revenues


      449,600


      100.0%


      445,923


      100.0%


      3,677


      0.8%

      Segment profit:


      —




      —







      Medicare - Internal


      10,771


      2.4%


      172,920


      38.8%


      (162,149)


      (93.8)%

      Medicare - External


      3,075


      0.7%


      5,051


      1.1%


      (1,976)


      (39.1)%

      IFP and Other - Internal


      2,162


      0.5%


      4,087


      0.9%


      (1,925)


      (47.1)%

      IFP and Other - External


      472


      0.1%


      1,121


      0.3%


      (649)


      (57.9)%

      Segment profit


      16,480


      3.7%


      183,179


      41.1%


      (166,699)


      (91.0)%

      Corporate expense


      29,693


      6.6%


      17,834


      4.0%


      11,859


      66.5%

      Amortization of intangible assets


      23,513


      5.2%


      23,514


      5.3%


      (1)


      —%

      Goodwill impairment charges


      386,553


      86.0%


      —


      —%


      386,553


      NM

      Interest expense


      9,619


      2.1%


      8,591


      1.9%


      1,028


      12.0%

      Other (income) expense, net


      (696)


      (0.2)%


      135


      —%


      (831)


      NM

      Income (loss) before income taxes


      $      (432,202)


      (96.1)%


      $       133,105


      29.8%


      $      (565,307)


      (424.7)%


      NM = Not meaningful



      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020





      (in thousands, except percentages)


      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change














      Medicare - Internal


      $       844,894


      79.5%


      $       667,293


      76.1%


      $       177,601


      26.6%

      Medicare - External


      189,563


      17.8%


      155,660


      17.7%


      33,903


      21.8%

      IFP and Other - Internal


      19,687


      1.9%


      32,271


      3.7%


      (12,584)


      (39.0)%

      IFP and Other - External


      8,271


      0.8%


      22,126


      2.5%


      (13,855)


      (62.6)%

      Net revenues


      1,062,415


      100.0%


      877,350


      100.0%


      185,065


      21.1%

      Segment profit:













      Medicare - Internal


      84,345


      7.9%


      296,865


      33.8%


      (212,520)


      (71.6)%

      Medicare - External


      2,622


      0.2%


      5,944


      0.7%


      (3,322)


      (55.9)%

      IFP and Other - Internal


      2,819


      0.3%


      4,269


      0.5%


      (1,450)


      (34.0)%

      IFP and Other - External


      245


      —%


      1,910


      0.2%


      (1,665)


      (87.2)%

      Segment profit


      90,031


      8.5%


      308,988


      35.2%


      (218,957)


      (70.9)%

      Corporate expense


      98,869


      9.3%


      259,778


      29.6%


      (160,909)


      (61.9)%

      Change in fair value of contingent consideration liability


      —


      —%


      19,700


      2.2%


      (19,700)


      (100.0)%

      Amortization of intangible assets


      94,056


      8.9%


      94,056


      10.7%


      —


      —%

      Loss on extinguishment of debt


      11,935


      1.1%


      —


      —%


      11,935


      NM

      Goodwill impairment charges


      386,553


      36.4%


      —


      —%


      386,553


      NM

      Interest expense


      33,505


      3.2%


      32,969


      3.8%


      536


      1.6%

      Other (income) expense, net


      (669)


      (0.1)%


      (358)


      —%


      (311)


      86.9%

      Income (loss) before income taxes


      $      (534,218)


      (50.3)%


      $       (97,157)


      (11.1)%


      $      (437,061)


      449.9%


      NM = Not meaningful


      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and twelve months ended December 31, 2021 and 2020, for those submissions that are commissionable (compensated through commissions received from carriers):



      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Medicare Advantage


      669,079


      330,604


      1,190,530


      644,669

      Medicare Supplement


      1,631


      2,955


      4,508


      9,119

      Prescription Drug Plans


      34,762


      10,293


      42,469


      16,762

      Total Medicare - Commissionable Submitted Policies


      705,472


      343,852


      1,237,507


      670,550

      The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for the three and twelve months ended December 31, 2021 and 2020. Only commissionable policies are used to calculate our LTV.

      Medicare - Internal



      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Medicare Advantage


      508,004


      250,251


      903,808


      478,863

      Medicare Supplement


      527


      1,514


      1,229


      3,116

      Prescription Drug Plans


      17,481


      8,263


      24,006


      13,582

      Total Medicare - Internal Commissionable Approved Submissions


      526,012


      260,028


      929,043


      495,561

      Medicare - External



      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Medicare Advantage


      145,616


      77,669


      266,795


      158,325

      Medicare Supplement


      708


      1,219


      2,531


      5,254

      Prescription Drug Plans


      11,628


      1,798


      12,344


      3,036

      Total Medicare - External Commissionable Approved Submissions


      157,952


      80,686


      281,670


      166,615

      The following table presents the LTV per Approved Submission by product for the Medicare segments, adjusted for the impact of the Lookback Adjustments, for the three and twelve months ended December 31, 2021 and 2020:



      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Medicare Advantage


      $           810


      $           949


      $           842


      $           900

      Medicare Supplement


      $           683


      $           934


      $           856


      $           849

      Prescription Drug Plans


      $           215


      $           213


      $           215


      $           215

      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and twelve months ended December 31, 2021 and 2020, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:



      Three months ended
      Dec. 31, 2021


      Three months ended
      Dec. 31, 2020


      Twelve months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2020

      Medicare Advantage


      12,711


      23,993


      23,414


      44,799

      Medicare Supplement


      3,223


      3,520


      8,242


      8,782

      Prescription Drug Plans


      2,478


      2,994


      4,696


      5,781

      Total Medicare - Non-commissionable Submitted Policies


      18,412


      30,507


      36,352


      59,362

      The following table sets forth the components of our results of operations for each quarter of 2021 (unaudited):

      (in thousands)


      Three months ended
      Mar. 31, 2021


      Three months ended
      Jun. 30, 2021


      Three months ended
      Sep. 30, 2021


      Three months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2021

      Net revenues:











      Commission


      $       173,981


      $       147,508


      $       174,948


      $       384,826


      $       881,263

      Enterprise


      30,198


      49,394


      36,786


      64,774


      181,152

      Net revenues


      204,179


      196,902


      211,734


      449,600


      1,062,415

      Operating expenses:











      Cost of revenue


      48,375


      37,442


      53,632


      99,886


      239,335

      Marketing and advertising


      54,484


      55,735


      59,511


      195,411


      365,141

      Customer care and enrollment


      47,094


      61,927


      87,813


      123,331


      320,165

      Technology


      9,617


      11,983


      11,651


      15,178


      48,429

      General and administrative


      19,693


      25,251


      24,232


      29,007


      98,183

      Amortization of intangible assets


      23,514


      23,515


      23,514


      23,513


      94,056

      Goodwill impairment charges


      —


      —


      —


      386,553


      386,553

      Total operating expenses


      202,777


      215,853


      260,353


      872,879


      1,551,862

      Income (loss) from operations


      1,402


      (18,951)


      (48,619)


      (423,279)


      (489,447)

      Interest expense


      8,688


      8,277


      6,921


      9,619


      33,505

      Loss on extinguishment of debt


      —


      11,935


      —


      —


      11,935

      Other (income) expense, net


      13


      44


      (30)


      (696)


      (669)

      Income (loss) before income taxes, net


      (7,299)


      (39,207)


      (55,510)


      (432,202)


      (534,218)

      Income tax expense (benefit)


      (31)


      (32)


      (79)


      118


      (24)

      Net income (loss)


      $         (7,268)


      $        (39,175)


      $        (55,431)


      $      (432,320)


      $      (534,194)

      Net income (loss) attributable to noncontrolling interests


      (5,178)


      (27,186)


      (35,248)


      (277,225)


      (344,837)

      Net income (loss) attributable to GoHealth, Inc.


      $         (2,090)


      $        (11,989)


      $        (20,183)


      $      (155,095)


      $      (189,357)

      The following table sets forth the share-based compensation expense embedded in the operating expense line items for each quarter of 2021 (unaudited):

      (in thousands)


      Three months ended
      Mar. 31, 2021


      Three months ended
      Jun. 30, 2021


      Three months ended
      Sep. 30, 2021


      Three months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2021

      Marketing and advertising


      $             337


      $             426


      $             698


      $             647


      $          2,108

      Customer care and enrollment


      796


      1,043


      957


      979


      3,775

      Technology


      747


      1,133


      910


      985


      3,775

      General and administrative


      3,232


      4,997


      4,824


      4,586


      17,639

      Total share-based compensation


      $          5,112


      $          7,599


      $          7,389


      $          7,197


      $         27,297

      The following table sets forth operating segment results for each quarter of 2021 (unaudited):

      (in thousands)


      Three months ended
      Mar. 31, 2021


      Three months ended
      Jun. 30, 2021


      Three months ended
      Sep. 30, 2021


      Three months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2021

      Net revenues:











      Medicare - Internal


      $       157,353


      $       160,433


      $       158,605


      $       368,503


      $       844,894

      Medicare - External


      39,500


      31,379


      46,237


      72,447


      189,563

      IFP and Other - Internal


      3,975


      3,788


      5,742


      6,182


      19,687

      IFP and Other - External


      3,351


      1,302


      1,150


      2,468


      8,271

      Net revenues


      $       204,179


      $       196,902


      $       211,734


      $       449,600


      $    1,062,415

      Segment profit (loss):











      Medicare - Internal


      $         46,443


      $         31,257


      $         (4,126)


      $         10,771


      $         84,345

      Medicare - External


      (631)


      (1,688)


      1,866


      3,075


      2,622

      IFP and Other - Internal


      (729)


      (800)


      2,186


      2,162


      2,819

      IFP and Other - External


      160


      (57)


      (330)


      472


      245

      Segment profit


      $         45,243


      $         28,712


      $            (404)


      $         16,480


      $         90,031

      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for each quarter of 2021 (unaudited):

      (in thousands, except percentages)


      Three months ended
      Mar. 31, 2021


      Three months ended
      Jun. 30, 2021


      Three months ended
      Sep. 30, 2021


      Three months ended
      Dec. 31, 2021


      Twelve months ended
      Dec. 31, 2021

      Net revenues


      $    204,179


      $    196,902


      $    211,734


      $    449,600


      $  1,062,415

      Net income (loss)


      (7,268)


      (39,175)


      (55,431)


      (432,320)


      (534,194)

      Interest expense


      8,688


      8,277


      6,921


      9,619


      33,505

      Income tax expense (benefit)


      (31)


      (32)


      (79)


      118


      (24)

      Depreciation and amortization expense


      25,367


      25,738


      26,070


      30,332


      107,507

      EBITDA


      26,756


      (5,192)


      (22,519)


      (392,251)


      (393,206)

      Loss on extinguishment of debt (1)


      —


      11,935


      —


      —


      11,935

      Goodwill impairment charges (2)


      —


      —


      —


      386,553


      386,553

      Share-based compensation expense (3)


      5,112


      7,599


      7,389


      7,197


      27,297

      Loss on sublease (4)


      —


      —


      1,062


      —


      1,062

      Legal fees (5)


      180


      —


      —


      —


      180

      Adjusted EBITDA


      $      32,048


      $      14,342


      $     (14,068)


      $        1,499


      $      33,821

      Adjusted EBITDA margin


      15.7%


      7.3%


      (6.6)%


      0.3%


      3.2%









      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents goodwill impairment charges related to the Medicare— Internal and Medicare— External reporting units for the three months ended December 31, 2021.

      (3)

      Represents non-cash share-based compensation expense relating to equity awards.

      (4)

      Represents the loss related to a sublease agreement entered into during the twelve months ended December 31, 2021.

      (5)

      Represents non-recurring legal fees unrelated to our core operations.

      SOURCE GoHealth, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.